FCGR3A and plasmacytoma: Additionally, our in vitro assay showed an increase in daratumumab-mediated ADCC activity when PBMCs isolated from participants were incubated with RPMI-8226 plasmacytoma cells, which was then nullified in the presence of antibodies blocking CD16 and CD32 receptors.